INTERMOUNTAIN HEALTH CARE, INC.

Newly diagnosed heart failure patients with atrial fibrillation (A-fib) have a poor prognosis, prompting researchers to urge doctors to screen for A-fib. Patients with A-fib and heart failure with reduced ejection fraction (HFrEF) face particularly poor outcomes, necessitating more aggressive treatment regimens.

A real-world study confirms RSV vaccines, Arexvy and Abrysvo, offer 80% protection against severe illness and hospitalization for seniors aged 60 and over, with significant benefits for those 75 and older. Published in The Lancet, the study highlights the vaccine's effectiveness and potential cost savings.

Real-world study confirms RSV vaccine offers 80% protection against severe illness/hospitalization for seniors aged 60 and over, with significant benefits for those aged 75+.